Yearly STL Archives: 2010

The Role and Topical Management of Staphylococcus aureus in Atopic Dermatitis (Family Practice)

Atopic dermatitis (AD), or eczema, is a common, chronic, relapsing, genetically determined inflammatory skin disorder. This article discusses the role of Staphylococcus aureus (S. aureus) as a factor to consider.

Topical Management of Rosacea

This article reviews the various subtypes of rosacea, their clinical presentations, and the considerations in choosing the optimal therapeutic options. The importance of tailored treatment is discussed as well as topical therapies.

Head Lice: A Review of Topical Therapies and Rising Pediculicidal Resistance (Pharmacist Edition)

Head lice infestation is a common problem for children in Canada. Diagnosis, and treatment are discussed as well as the problem of heritable resistance, and alternate treatments.

Topical Management of Recalcitrant Psoriasis & Eczema

Psoriasis and eczema can at times be recalcitrant to conservative topical treatment. This article focuses on corticosteroid strength and their appropriate uses for various presentations.

Therapeutic Moisturizers in Eczema and Xerosis Management (Pharmacist Edition)

Eczema is a chronic relapsing dermatitis and, as such, it is imperative to maintain the hydration and barrier function of the skin in these patients with daily moisturizer use. This article discusses TEWL, ceramide and urea based moisturizers, and other ways to maintain barrier function.

Update on Drugs and Drug News: November 2010

Update on drugs, approval dates, and comments. Drospirenone /ethinyl estradiol /levomefolate calcium + levomefolate calcium tablets (Beyaz™), Imiquimod 5% cream are covered.

The Role and Topical Management of Staphylococcus aureus in Atopic Dermatitis (Pediatric)

This article discusses the role of S. aureus, on atopic dermatitis. Taking a proactive approach to treatment, and control S. aureus may have benefits for the management of inflammation.

Skin Barrier Repair in the Management of Atopic Dermatitis (Pediatric Edition)

In this article, the pathogenesis of atopic dermatitis and the role of weakened skin barrier and inflammation is discussed in detail. Potential treatment and management strategies that address this problem, and the benefits of this approach are highlighted.

Benzoyl Peroxide: Enhancing Antibiotic Efficacy in Acne Management

Benzoyl peroxide is one of the most widely used topical agents for acne. This article discusses the anti-inflammatory and comedolytic effects of benzoyl peroxide.

Polycystic Ovary Syndrome and Acne

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive aged women. This article will review the treatments for acne due to androgen excess in PCOS women.

Head Lice: A Review of Topical Therapies and Rising Pediculicidal Resistance

Head lice infestations (Pediculosis capitis) are a worldwide problem with prevalence estimates typically ranging between 1-3% in elementary school aged children. Although this obligate parasite is a nuisance, infestation does not pose a health risk.

Update on Drugs and Drug News: October 2010

October 2010: Update on drugs, approval dates, and comments. Velaglucerase alfa (VPRIV®), and recent news with Health Canada.

Nanodermatology: A Glimpse of Caution Just Beyond the Horizon – Part II

Nanotechnology applies the unique properties of matter on the nanoscale (1000 nm and smaller) for the purposeful design of new materials. Dermatology is already one of the leading beneficiaries of nanotechnology.

Skin Barrier Repair in the Management of Atopic Dermatitis

The term “atopy” was first coined by Cooke and Coca in 1923, derived from the Greek word atopos, which means out of place and denotes an immune reaction that is “strange or eccentric”. Atopic dermatitis (AD) is a chronic, waxing and waning, often symmetric inflammatory eruption that is characterized by pruritus and xerosis.

The Current Management of Delusional Parasitosis and Dermatitis Artefacta

Psychocutaneous disorders involve a unique and somewhat difficult patient population. This paper describes an effective interpersonal approach and appropriate drug therapy for patients with delusional disorders and dermatitis artefacta.

Update on Drugs and Drug News: September 2010

Update on drugs, approval dates, and comments. Velaglucerase alfa (VPRIV®) and Health Canada labelling changes for isopropyl myristate 50% rinse (Resultz®, Nycomed) to include the treatment of lice in children =2 years of age are covered.

The Management of Chronic Pruritus in the Elderly

The elderly in North America is the fastest growing segment of the population and their most common skin complaint is pruritus. This article outlines the therapeutic challenges with this population.

Nanodermatology: A Bright Glimpse Just Beyond the Horizon – Part I

Nanotechnology is a relatively new branch of engineering that is making rapid inroads in medicine and dermatology. This article summarizes some of the recent and anticipated advances in nanotechnology for dermatology. In part II, the author addresses the chief concerns of nanotechnology.

Male Skin Care

For decades, skin care has primarily been considered to be the domain of women, but recently, an increasing number of men are involved. This article delves into similarities and differences in gender as it relates to skincare, and the complexities of skincare for men.

Update on Drugs and Drug News: July-August 2010

Update on drugs, approval dates, and comments. Belimumab (Benlysta®), Adapalene 0.1% gel, Antiseborrheic compound (K301/Kaprolac®) are covered.

Chemotherapy-Induced Hair Loss

Chemotherapy-induced hair loss occurs with an estimated incidence of 65%. This article discusses hair loss, topical minoxidil, scalp cooling and chemotherapy induced hair loss.

Systemic Retinoids: Chemoprevention of Skin Cancer in Transplant Recipients

Solid organ transplant recipients have an increased incidence of skin cancer, resulting in significant morbidity and mortality post-transplantation. This article studies systemic retinoids, and other chemopreventative agents for high risk patients.

Update on the Management of Actinic Keratoses

Actinic keratoses (AKs), or solar keratoses, are pre-malignant cutaneous lesions that predominantly manifest in sun-exposed areas. They are one of the most common skin conditions seen by dermatologists, preceded only by acne vulgaris and dermatitis.

Skin Barrier Repair in the Management of Atopic Dermatitis (Pharmacist Edition)

Atopic dermatitis (AD) is a chronic, waxing and waning, often symmetric inflammatory eruption that is characterized by pruritus and xerosis. This article discusses the role of creams in normalizing the barrier function early, and preventing inflammation processes from starting.

Update on the Management of Actinic Keratoses (Pharmacist Edition)

Actinic keratoses (AKs), or solar keratoses, are pre-malignant cutaneous lesions that predominantly manifest in sun-exposed areas. This article covers treatment regimens, sun protection, and the role that physicians play in improving patient awareness.

Smoking and Skin Disease

Tobacco smoking is a serious and preventable health hazard that can cause or exacerbate a number of diseases and shorten life expectancy. This article delves into the role of smoking as an etiologic factor in the development of skin disease.

New and Existing Therapies for Chronic Hand Dermatitis

Hand dermatitis (HD) is a common skin disorder affecting individuals of all ages. This article discusses diagnostics, individualizing treatments, lifestyle modifications, and outcomes.

Sunscreens in the Management of Photodermatoses

Key to the management of photodermatoses is photoprotection, which includes seeking shade; wearing wide brimmed hats, and sunglasses; and applying sunscreens. This article discusses sunscreens, sun protection, UVA, UVB, and its role in managing various skin conditions.

Update on Drugs and Drug News: June 2010

Update on CD56-binding monoclonal antibody (huN901) + maytansinoid cytotoxic agent (DM1) IMGN901, Small molecule oxychlorine compound (Microcyn® Skin and Wound HydroGel), Antifungal agent (K101/Kaprolac®).

Update on Drugs and Drug News: May 2010

Update on drugs, approval dates, and comments. Imiquimod 3.75% cream (Zyclara™), Adapalene 0.1% lotion (Differin®), Polidocanol injection (Asclera®) are covered.

Current Management of Actinic Keratoses

An actinic keratosis is a pre-malignant cutaneous lesion that frequently manifests in sun-exposed areas of the skin as a small, rough, scaly erythematous papule. Therapy choices are guided by efficacy, adverse effects, cosmetic results, and patient compliance.

Therapeutic Update on Seborrheic Dermatitis

Seborrheic dermatitis is a recurrent, usually mild, skin disorder with typical clinical manifestations. This article will review the available treatments for this common dermatologic problem.

IN MEMORIAM Penelope Gray-Allan

We regret to announce the sudden passing of our Managing Editor, Penelope Gray-Allan.

Update on Drugs and Drug News: April 2010

Update on drugs, approval dates, and comments. Collagenase clostridium histolyticum (XIAFLEX™), HPV quadrivalent recombinant vaccine (Gardasil®), Velaglucerase alfa (VPRIV™), Agalsidase alfa (REPLAGAL®), Adalimumab (Humira®) are covered.

What is Needed for a Sunscreen to Provide Complete Protection

In order to achieve complete protection against the cumulative detrimental effects from sun exposure, topical strategies must shield against the range of solar wavelengths that can damage the skin. Existing examples of infrared-protective active agents include mitochondrially targeted antioxidants.

Alefacept Treatment for Chronic Plaque Psoriasis

Biologic agents were introduced during the past decade as a new class of treatments for chronic psoriasis. This review will discuss data from clinical trials that have provided new insights into the efficacy, safety, and cost effectiveness of alefacept as a treatment for psoriasis.

Update on Drugs and Drug News: March 2010

Update on Hyaluronic acid dermal filler + 0.3% lidocaine JUVÉDERM® XC, Hyaluronic acid dermal filler + 0.3% lidocaine RESTYLANE®-L PERLANE®-L, and news on labeling changes regarding possible hepatic effects of diclofenac sodium topical gel 1% (Voltaren® Gel).

Current Concepts in Laser Tattoo Removal

Today, more than 10% of the Western population has at least 1 tattoo, with prevalence of up to one-fourth in the cohort younger than 30 years of age. This article provides an overview of applicable laser systems and therapeutic strategies for optimized tattoo removal.

Does Diet Really Affect Acne?

A review of studies, reviewing association between a high-glycemic-load diet, hormonal mediators, and acne risk.

Update on Drugs and Drug News: February 2010

Update on Imiquimod 3.75% Cream Zyclara™, Acyclovir + Hydrocortisone Cream Xerclear®/Lipsovir®, as well as drug news on Titanium dioxide (TiO2).

POPULAR